3-[(1S,2S)-1-{5-[(4S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-2-({(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetra hydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-1H-indol-1-yl}-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4H)-one

1,2,4-Oxadiazol-5(4H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4 ,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-

3-[(1S,2S)-1-{5-[(4S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-2-({(4S)-2-(4-fluor-3,5-dimethylphenyl)-3-[3-(4-fluor-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahy dro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-1H-indol-1-yl}-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4H)-on

3-[(1S,2S)-1-{5-[(4S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-2-({(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetra hydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-1H-indol-1-yl}-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4H)-one

3-[(1S,2S)-1-{5-[(4S)-2,2-Diméthyltétrahydro-2H-pyran-4-yl]-2-({(4S)-2-(4-fluoro-3,5-diméthylphényl)-3-[3-(4-fluoro-1-méthyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-méthyl-2,4,6,7-tétra hydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-1H-indol-1-yl}-2-méthylcyclopropyl]-1,2,4-oxadiazol-5(4H)-one

2212020-52-3

3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one

GLP-1 receptor agonist 1

GLP1R_HUMAN

Glucagon-like peptide 1 receptor

MFCD31807602

Orforglipron